- Department of Neurosurgery and Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
- Department of General Surgery, Vanderbilt University Medical Center, Nashville, TN, USA
- Vanderbilt School of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
- Division of Otolaryngology, Vanderbilt University Medical Center, Nashville, TN, USA
- Division of Endocrinology, Vanderbilt University Medical Center, Nashville, TN, USA
- Department of Neurosurgery, University of Arkansas for Medical Sciences, Little Rock, AR, USA
- Wake Forest University School of Medicine, Wake Forest University Baptist Medical Center, Winston-Salem, NC, USA
Correspondence Address:
Jonathan A. Forbes
Division of Endocrinology, Vanderbilt University Medical Center, Nashville, TN, USA
DOI:10.4103/2152-7806.81723
Copyright: © 2011 Forbes JA. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.How to cite this article: Forbes JA, Wilkerson J, Chambless L, Shay SD, Elswick CM, Abblitt PW, Adogwa O, Russell P, Weaver KD, Allen GS, Utz AL. Safety and cost effectiveness of early discharge following microscopic trans-sphenoidal resection of pituitary lesions. Surg Neurol Int 28-May-2011;2:66
How to cite this URL: Forbes JA, Wilkerson J, Chambless L, Shay SD, Elswick CM, Abblitt PW, Adogwa O, Russell P, Weaver KD, Allen GS, Utz AL. Safety and cost effectiveness of early discharge following microscopic trans-sphenoidal resection of pituitary lesions. Surg Neurol Int 28-May-2011;2:66. Available from: http://sni.wpengine.com/surgicalint_articles/safety-and-cost-effectiveness-of-early-discharge-following-microscopic-trans-sphenoidal-resection-of-pituitary-lesions/
Abstract
Background:Inpatient hospitalization following trans-sphenoidal resection of a pituitary neoplasm has traditionally involved a hospital stay of 2 days or more. It has been the policy of the senior pituitary neurosurgeon (GSA) since February 2008 to allow discharge home on postoperative day (POD) 1 if thirst mechanism is intact and the patient is tolerating oral hydration. The goal of this study was to evaluate the safety and cost-effectiveness of this practice.
Methods:We reviewed the charts of 30 patients, designated the early discharge group, who consecutively underwent microscopic trans-sphenoidal resection from February 2008 to December 2009. We then reviewed the charts of 30 patients, designated the standard discharge group, who consecutively underwent trans-sphenoidal resection from May 2007 to February 2008 before discharge home on POD1 was considered an appropriate option. Safety and cost-effectiveness of the two patient groups were retrospectively evaluated.
ResultsPatients in the early discharge group went home, on average, on POD 1.3. Following exclusion of two outliers, the average date of discharge of patients in the standard discharge group was POD 2.2. The policy of early discharge saved an average of $1,949 per patient-approximately 4% the total cost of the procedure. Trends toward decreased costs did not reach statistical significance. While no patient suffered any measurable morbidity as a result of early discharge home, 1 in 3 patients in the early discharge group required unscheduled postoperative re-evaluation-a figure significantly higher than the standard discharge group.
Conclusions:At a dedicated pituitary center with the resources to closely monitor outpatient endocrinological and postsurgical issues, early discharge home following trans-sphenoidal surgery is a safe option that is associated with an increase in the number of unscheduled postoperative visits and a trend toward lower costs.
Keywords: Diabetes insipidus, early discharge, pituitary surgery, SIADH, trans-sphenoidal
INTRODUCTION
The cost of medicine in the United States has commanded much attention in recent years. More money per person is spent on health care in the United States than in any other nation in the world.[
Pituitary adenomas are estimated to have an overall prevalence of 16.7% with an annual incidence of approximately 7,000 new cases/year.[
Operative costs include the costs of the operating room and its staff, operating room equipment, and care provided by the anesthesiology and surgical teams. Operative time is the predominant factor in determining the total operative cost; the joint procedure with the ENT and neurosurgical teams has traditionally required approximately 2-3 hours to perform at our center. Previous reports have suggested that endoscopic trans-sphenoidal resection of pituitary lesions may require less operative time than microscopic resection.[
Postoperative costs can be further subdivided into costs incurred during inpatient and outpatient care. Costs related to postoperative inpatient care are influenced by time spent in the hospital. Average length of stay following trans-sphenoidal resection is variable among institutions (see
Postoperative outpatient costs have been defined as all expenditures relating to the operation incurred during the period of time following discharge from the hospital up to and including the date of the routine scheduled 6-week follow-up visit. Included in this figure are costs of unscheduled trips to the emergency department (ED), which often involve additional charges relating to ancillary imaging and/or laboratory analysis, in addition to any other costs relating to patient contact and/or evaluation prior to and including the scheduled 6-week follow-up visit. These figures include the costs of postoperative clinical communication between the patient and endocrinological team in addition to the costs of outpatient laboratory analysis ordered in those patients who report symptoms concerning for possible water and electrolyte imbalance following discharge. Scheduled visits 1 week following the operation in ENT clinic and approximately 6 weeks following the operation in neurosurgery and endocrinology clinics are also included in this group of costs.
Since February 2008, it has been the policy at VUMC for the senior pituitary surgeon (GSA) to encourage discharge home on postoperative day (POD) 1 following microscopic trans-sphenoidal resection of a pituitary lesion if thirst mechanism is intact and the patient is able to hydrate comfortably. The change in policy to allow for early discharge home in select patients was instituted through the collaborative efforts of members of the Vanderbilt Pituitary Center in February 2008. Early discharge is only made possible via extensive pre-and peri-operative education by the neurosurgical, otolaryngological, and endocrinological teams. Additionally, early discharge home would not be feasible without readily available outpatient communication and surveillance with all services. Unanticipated outpatient contact at VUMC is usually initiated through the endocrinology service.
MATERIALS AND METHODS
A total of sixty consecutive patients who underwent microscopic trans-sphenoidal resection of pituitary lesions between May 2007 and June 2009 by the GSA at VUMC were included in this retrospective study. Thirty of the patients in this group were underwent operations between May 2007 and February 2008, when discharge home on POD2 was the standard. The remaining 30 were operated between February 2008 and December 2009. In the latter group, discharge home on POD1 was allowed and even encouraged, when certain criteria were met.
Of the 30 patients in the group operated on prior to February 2008, 14 (47%) were male and 16 (53%) were female. A total of 87% of tumors were macroadenomas. One pituicytoma and one Rathke's cleft cyst were included in this group. A total of 53% of tumors were non-secreting and 10% of were corticotroph adenomas associated with Cushing's disease.
Of the 30 patients operated after February 2008, 13 (43%) were male and 17 (57%) were female. A total of 83% of tumors were macroadenomas. Of the cases in this group that were pituitary adenomas, 40% of tumors were non-secreting and 17% of were corticotroph adenomas associated with Cushing's disease. A summary of these clinical data is available in
Description of the standard operative procedure
The following operative procedure is utilized by the senior pituitary surgeon (GSA) at Vanderbilt Pituitary center, who uses the microscope for sublabial trans-sphenoidal procedures. The patient is brought to the operating room, intubated, and placed in Mayfield pins. A navigation protocol MRI scan is registered to the patient using software included on a StealthStation (Medtronic, Inc.) to allow for intra-operative use of frameless stereotaxy. A hemitransfixion incision is made and followed by a subperichondrial dissection, which is carried posteriorly to the sphenoid rostrum, and inferiorly to the nasal floor along the entire length of the septum. The cartilaginous septum is disarticulated at the bony/cartilaginous junction and the sphenoid is entered bilaterally at the rostrum and opened widely. A sublabial incision is then made across the central incisors, taking care to ensure that a mucosal cuff remains. A Hardy retractor is then placed, allowing a clear view of the sella, and a drill is then used to remove the anterior sella floor. The dura mater is a cauterized and opened with a cruciate incision. The pituitary lesion is then resected in the standard fashion using a combination of ringed curettes, pituitary instrumentation, and suction. Once the tumor is removed, the Hardy retractor is removed and the nose is returned to its normal anatomic position. The cartilaginous septum is fixated to the maxillary crest using an absorbable monofilament suture. The sublabial incision is then closed using an absorbable suture in a horizontal mattress fashion. The hemitransfixion incision is closed absorbable suture in a simple interrupted fashion. Several tacking sutures are placed through the septum to reapproximate the nasal mucosal flaps. Doyle splints are applied and sutured in place with a nonabsorbable monofilament suture. The patient is taken out of pins and extubated.
It is important to note that many centers across the country have transitioned from a microscopic to an endoscopic endonasal approach. While cost and quality of life comparisons between the two approaches is beyond the scope of this manuscript, it deserves mention that patients who undergo endonasal endoscopic approaches often require one or more additional postoperative visits for nasal debridement.
Description of endocrinological postoperative protocol
All patients at VUMC receive stress dose glucocorticoids prior to the operation and are later discharged home on postoperative glucocorticoid supplementation for 6 weeks. The HPA axis testing is delayed until the 6 week postoperative endocrinology visit.
All patients are evaluated regarding their ability to orally hydrate postoperatively. Labs—including serum osmolarity, serum sodium, and urine-specific gravity—are obtained every 6 hours, beginning at the completion of the surgical procedure. Any patient who communicates persistent difficulty in quenching his/her thirst or develops laboratory evidence of DI is placed on scheduled desmopressin. All patients diagnosed with DI are given a prescription of as needed (PRN) desmopressin to fill in the event that they are not able to satisfy their thirst mechanism with oral hydration alone prior to discharge. Patients are instructed to drink to quench their thirst and to contact the Pituitary Center or Endocrinologist on-call (available 24 hours a day, 7 days a week) with persistent excessive urine output or other classic symptoms of water or electrolyte imbalance.
Operations are typically performed on Tuesdays, with discharge following uncomplicated cases on Wednesday afternoon. Following discharge, patients who report symptoms concerning for DI undergo laboratory analysis within 24 hours of symptom onset—this is accomplished in an outpatient clinic, whenever possible. In the setting of acute emergency, weekend events, or events that occur long distances from the medical center, labs are obtained in the ED. Routine laboratory analysis in the absence of symptoms following discharge is not conducted. All patients are formally reevaluated with serum and urinary laboratory analysis at 6 weeks time for the presence of DI.
Routine postoperative imaging is obtained immediately prior to the 6-week follow-up visit.
Data collection
The sum operative costs of each patient were obtained as “charge data” from the VUMC Billing Department and assessed in a retrospective fashion. Study data were collected and managed using REDCap electronic data capture tools[
Statistical considerations
Statistical analyses were performed in Graphpad Prism 5.03 (Graphpad Software Inc., La Jolla, CA). An unpaired t-test was used to compare the following data sets: total costs, operative costs, postoperative inpatient costs, and postoperative outpatient costs in both the early and standard discharge groups. The unpaired t-test was then repeated for total and postoperative inpatient costs following exclusion of two outliers from the standard discharge group. A final unpaired t-test was used to compare and assess the percentage of patients in each group requiring return unscheduled visits in the early and standard discharge groups for statistical significance.
RESULTS
Despite trends toward lower postoperative inpatient and total costs (respective P-values of 0.169 and 0.188) in the early discharge group, no significant difference was observed. The difference in postoperative inpatient and total costs remained statistically insignificant (respective P-values of 0.24 and 0.42) after exclusion of two outliers who experienced prolonged hospital stays in the standard discharge group. In addition to these findings, no significant difference was observed between operative and postoperative outpatient costs in the early and standard discharge groups. The results of these analyses are summarized in
Figure 3
An unpaired t-test was used to compare the following data sets: (a) total costs, (b) operative costs, (c) postoperative inpatient costs, and (d) postoperative outpatient costs in both the early (< Feb 2008) and standard (> Feb 2008) discharge groups. Despite a trend toward lower postoperative inpatient and total costs, no significant difference between was observed in all individual cost measures. Differences in post-operative inpatient and total costs remained statistically insignificant after exclusion of two outliers who experienced prolonged hospital stays in the standard discharge group
A summary of postoperative complications and other characteristics of the two patient groups is provided in
Patients operated on or before February 2008 were discharged home on an average of POD 3.0. This figure includes two patients who experienced prolonged hospital stays of 7 and 21 days for postoperative CSF leak and respiratory distress, respectively. When these two outliers are excluded the remaining patients stayed an average of 2.2 PODs. A total of six patients (20%) in this group developed DI and were discharged home an average of 2.7 days following the surgery. In this group, no patients presented to the ED in the initial 36 hours following discharge, although four patients did return to the ED prior to 6-week follow-up for various causes [
Average postoperative inpatient costs based on charge data were approximately $8,438 (27.3%) less in patients operated on after February 2008 (approximately $5,000 dollars per day of hospital stay). These differences in average total costs between the two groups are depicted in
Figure 5
Total costs of the surgical procedure in early and standard discharge groups broken down into subcategories. Average total costs based on charge data were approximately $8,359 less in patients operated on after February 2008. When this data was reanalyzed without 2 outliers, charge data indicated that the policy of early discharge saved $1,949 per patient (or $2,165 per day of hospital stay)
DISCUSSION
Variability exists among different institutions regarding the postoperative care of patients who have undergone trans-sphenoidal resection of pituitary lesions. Below, common reasons that patients are kept in the hospital postoperatively for a prolonged period are addressed.
Patients require monitoring for major surgical complications
Surgical complications following trans-sphenoidal resection of a pituitary lesion have traditionally been designated as either major or minor. Major complications are conditions that require reoperation, have the potential to result in permanent neurologic deficit, or are potentially fatal.[
One other complication that sometimes arises well after the initial 24-hour postoperative period warrants further discussion. In patients with giant (>40 mm) pituitary neoplasms who undergo subtotal resection, hemorrhagic infarction in the subacute period following surgery has been described.[
In our series of 60 patients, one patient operated on after February 2008 required a return trip to the OR for visual deterioration relating to a parasellar hemorrhage detected 3 hours after surgery. Following return for hematoma evacuation, the patient's vision returned to baseline preoperative levels. While CSF leakage was encountered intraoperatively in 6 (10%) patients, there was only 1 postoperative CSF fistula (1.7%) in our series of 60 patients. This patient was treated successfully with a 5-day trial of lumbar drainage. Excluding one patient who required prolonged hospitalization for postoperative respiratory failure, the remaining four patients who suffered an intraoperative CSF leak but did not develop a postoperative CSF fistula were discharged home an average of 1.8 days following the operation. The overall rate of major complications in this series was 1/60 (1.7%).
Major surgical complications following trans-sphenoidal surgery are rare.[
Patients require monitoring for minor surgical complications
Minor surgical complications following trans-sphenoidal resection involve oral and rhinological issues that can include epistaxis, nasal septal perforation, nose deformity, and tooth denervation. This group has also traditionally included transient neurological impairment of optic or other adjacent cranial nerves, when present.[
The incidence of minor surgical complications is related to the method of exposure and wound closure. Regarding our protocol for wound care, Doyle splints are removed at the first postoperative visit with the ENT surgical team—approximately 1 week following the surgery. Using this protocol, we have had few complications. In our series of 60 patients, one patient who underwent trans-sphenoidal resection after February 2008 and was discharged on POD1 returned to the ED for reevaluation following passage of a large clot from his nasal stents approximately 36 hours following surgery. This episode resolved with observation alone and the patient was discharged home from the ED later that evening. When early discharge following pituitary surgery is considered, patients should be counseled regarding the possibility of passage of nasal clots, in addition other minor oral and rhinological complications in the perioperative period.
Patients require monitoring of hypothalamic—pituitary—adrenal axis function
Monitoring for hypothalamic—pituitary—adrenal (HPA) axis integrity may be performed in the early postoperative period or during the follow-up visit 6-8 weeks after discharge home on prophylactic glucocorticoid replacement. The authors have chosen to adopt the latter approach. High levels of accuracy regarding detection of postoperative AI using varying methods have been reported;[
Patients require monitoring of diabetes insipidus
Water and electrolyte disorders (WED) are common following trans-sphenoidal resection of pituitary lesions and have been linked to intraoperative manipulation of the neurohypophysis.[
In our series of 60 patients, 8 patients (13%) were found to develop DI. Of these eight patients, two were found to have persistent DI at 6-week follow-up and were maintained on a scheduled regimen of desmopressin supplementation; DI had resolved in both of these patients at 2-year follow-up. The five patients operated on during/after February 2008 who developed DI were discharged after an average length of stay of 1.6 days. Notably, one of these patients was diagnosed with DI following discharge from the hospital on POD1. No patient suffered any measurable morbidity relating to fluid or electrolyte imbalance as a result of early discharge home.
In patients with an intact thirst mechanism following trans-sphenoidal surgery who are able to hydrate themselves comfortably, it is the authors‘ belief that—assuming outpatient communication with a dedicated endocrinology team is readily available—the presence of diabetes insipidus should not represent a contraindication to early discharge home. Furthermore, as not all patients who develop DI in the postoperative period do so in the first 24 hours, or even the first 7 days,[
Patients require monitoring of hyponatremia
The prevalence of SIADH and hyponatremia following trans-sphenoidal surgery characteristically peaks approximately 7–9 days following the date of surgery.[
While postoperative hyponatremia is a concern, symptomatic postoperative hyponatremia has not been a significant problem at our institution. In our review of 60 patients, two patients (3%) developed symptomatic hyponatremia relating to SIADH [patients 39 and 52, see
DISCUSSION OF COSTS
We were intrigued to find that the length of stay accounted for such a small fraction of the costs of inpatient hospital stay. For example, cutting the postoperative hospital stay in half (from two postoperative days to one) only decreased the costs associated with inpatient hospital stay by 8.7%. Review of cost data would be useful for further characterization of this trend. Charge data presented above indicate that the policy of early discharge home resulted in savings of approximately $2,000 (or 4.4% of the total costs of the procedure) per patient. However, the benefits of cost savings associated with early discharge must be balanced against the risks and costs associated with outpatient access to medical care in the early postoperative period. In the analysis above, the practice of early discharge home resulted in a statistically significant increase in the number of unscheduled postdischarge return visits—specifically one in three patients required some form of outpatient evaluation. However, because the majority of these visits were accomplished in an outpatient setting outside of the ED (average cost for evaluation in outpatient setting of early discharge group in
CONCLUSIONS
Analysis of this series indicates that discharge on POD1 following trans-sphenoidal resection in patients with an intact thirst mechanism appears to be a safe option that is associated with an increase in the number of additional unscheduled visits for reevaluation. Early discharge was associated with a statistically insignificant trend in savings of approximately $2,000 per patient. While patient safety does not appear to be a concern following early discharge, patients should be counseled about the increased likelihood that additional unscheduled outpatient visits for clinical and laboratory reevaluation may be necessary.
References
1. Adams JR, Blevins LS, Allen GS, Verity DK, Devin JK. Disorders of water metabolism following transsphenoidal pituitary surgery: A single institution's experience. Pituitary. 2006. 9: 93-9
2. last accessed on 2010 Apr 6. Available from: http://www.cancer.org/docroot/CRI/content/CRI_2_4_1X_What_are_the_key_statistics_for_pituitary_tumors_61.asp?sitearea= .
3. Auchus RJ, Shewbridge RK, Shepherd MD. Which patients benefit from provocative adrenal testing after transsphenoidal pituitary surgery?. Clin Endocrinol. 1997. 46: 21-7
4. Barker FG, Klibanski A, Swearingen B. Transsphenoidal surgery for pituitary tumors in the United States, 1996-2000: Mortality, morbidity, and the effects of hospital and surgeon volume. J Clin Endocrinol Metab. 2003. 88: 4709-19
5. Barzaghi LR, Losa M, Giovanelli M, Mortini P. Complications of transsphenoidal surgery in patients with pituitary adenoma: Experience at a single centre. Acta Neurochir (Wien). 2007. 149: 877-86
6. Black PM, Zervas NT, Candia GL. Incidence and management of complications of transsphenoidal operation for pituitary adenomas. Neurosurgery. 1987. 20: 920-4
7. Boehnert M, Hensen J, Henig A, Fahlbusch R, Gross P, Buchfelder M. Severe hyponatremia after transsphenoidal surgery for pituitary adenomas. Kidney Int Suppl. 1998. 64: S12-4
8. Cappabianca P, Cavallo LM, Colao A, Del Basso De Caro M, Esposito F, Cirillo S. Endoscopic endonasal transsphenoidal approach: Outcome analysis of 100 consecutive procedures. Minim Invasive Neurosurg. 2002. 45: 193-200
9. Cho DY, Liau WR. Comparison of endonasal endoscopic surgery and sublabial microsurgery for prolactinomas. Surg Neurol. 2002. 58: 371-5
10. Chrousos GA, Kattah JC, Beck RW, Cleary PA. Side effects of glucocorticoid treatment. Experience of the optic neuritis treatment trial. JAMA. 1993. 269: 2110-
11. Ciric I, Ragin A, Baumgartner C, Pierce D. Complications of transsphenoidal surgery: Results of a national survey, review of the literature, and personal experience. Neurosurgery. 1997. 40: 225-36
12. Cockroft KM, Carew JF, Trost D, Fraser RA. Delayed epistaxis resulting from external carotid artery injury requiring embolization: A rare complication of transsphenoidal surgery: Case report. Neurosurgery. 2000. 47: 236-9
13. Cohen L, Counsell CM. Cost analysis of intermediate care versus intensive care for the neurosurgery patient. J Nurs Adm. 1996. 26: 3, 18-
14. Ezzat S, Asa S, Couldwell W, Barr C, Dodge W, Vance M. The prevalence of pituitary adenomas: A systematic review. Cancer. 2004. 101: 613-9
15. Han ZL, He DS, Mao ZG, Wang HJ. Cerebrospinal fluid rhinorrhea following trans-sphenoidal pituitary macroadenoma surgery: Experience from 592 patients. Clin Neurol Neurosurg. 2008. 110: 570-9
16. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap): A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009. 42: 377-81
17. Higgins TS, Courtemanche C, Karakla D, Strasnick B, Singh RV, Koen JL. Analysis of transnasal endoscopic versus transseptal microscopic approach for excision of pituitary tumors. Am J Rhinol. 2008. 22: 649-52
18. Himmelstein DU, Wright A, Woolhandler S. Hospital computing and the costs and quality of care: A national study. Am J Med. 2010. 123: 40-6
19. Inder WJ, Hunt PJ. Glucocorticoid replacement in pituitary surgery: Guidelines for perioperative assessment and management. J Clin Endocrinol Metab. 2002. 87: 2745-50
20. Klose M, Lange M, Kosteljanetz M, Poulsgaard L, Feldt-Rasmussen U. Adrenocortical insufficiency after pituitary surgery: An audit of the reliability of the conventional short synacthen test. Clin Endocrinol. 2005. 63: 499-505
21. last accessed on 2009 Aug 25. Available from: http://www.iedm.org/uploaded/pdf/juin05_en.pdf .
22. Kristof RA, Rother M, Neuloh G, Klingmüller D. Incidence, clinical manifestations, and course of water and electrolyte metabolism disturbances following transsphenoidal pituitary adenoma surgery: A prospective observational study. J Neurosurg. 2009. 111: 555-62
23. Marko NF, Gonugunta VA, Hamrahian AH, Usmani A, Mayberg MR, Weil RJ. Use of morning serum cortisol level after transsphenoidal resection of pituitary adenoma to predict the need for long-term glucocorticoid supplementation. J Neurosurg. 2009. 111: 540-4
24. Nishioka H, Ohno S, Ikeda Y, Ohashi T, Haraoka J. Delayed massive epistaxis following endonasal transsphenoidal surgery. Acta Neurochir (Wien). 2007. 149: 523-6
25. O’Malley BW, Grady MS, Gabel BC, Cohen MA, Heuer GG, Pisapia J. Comparison of endoscopic and microscopic removal of pituitary adenomas: Single-surgeon experience and the learning curve. Neurosurg Focus. 2008. 25: E10-
26. Patil CG, Lad SP, Harsh GR, Laws ER, Boakye M. National trends, complications, and outcomes following transsphenoidal surgery for Cushing's disease from 1993 to 2002. Neurosurg Focus. 2007. 23: E7-
27. Sata A, Hizuka N, Kawamata T, Hori T, Takano K. Hyponatremia after transsphenoidal surgery for hypothalamo-pituitary tumors. Neuroendocrinology. 2006. 83: 117-22
28. Sheehan JM, Sheehan JP, Douds GL, Page RB. Desmopressin use in patients undergoing transsphenoidal surgery for pituitary adenomas. Acta Neurochir (Wien). 2006. 148: 287-91
29. White DR, Sonnenburg RE, Ewend MG, Senior BA. Safety of minimally invasive pituitary surgery (MIPS) compared with a traditional approach. Laryngoscope. 2004. 114: 1945-8
30. last accessed on 2010 Apr 6. Available from: http://www.who.int/whosis/whostat/2009/en/index.html .
31. Zada G, Liu CY, Fishback D, Singer PA, Weiss MH. Recognition and management of delayed hyponatremia following transsphenoidal pituitary surgery. J Neurosurg. 2007. 106: 66-71